Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
This review summarizes Phase III clinical trial data available for fingolimod. The main purpose is to evaluate the benefit-risk profile of fingolimod, the first oral compound available for treatment of multiple sclerosis (MS) and just recently approved by the European authorities. The authors place...
| Main Authors: | , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2011
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173035/ |